Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Talzenna
Pharma
Pfizer eyes earlier Talzenna use after ph. 3 prostate cancer win
If approved, Talzenna would be the first PARP inhibitor to enter the HRR-mutant metastatic hormone-sensitive prostate cancer setting.
Angus Liu
Mar 19, 2026 6:45am
FDA advisors unanimously reject Pfizer's Talzenna expansion bid
May 22, 2025 10:20am
J&J, Pfizer and Roche face FDA questions over data applicability
May 16, 2025 3:52pm
FDA to host first oncology adcomm meeting under Makary
May 8, 2025 11:35am
Pfizer details survival win in bid for broad prostate cancer nod
Feb 13, 2025 10:00am
Pfizer targets broad Talzenna label in prostate cancer
Oct 10, 2024 10:18am
